Aclaris Therapeutics announced rapid and robust responses to its bispecific antibody ATI-052 in atopic dermatitis and asthma trials, with a favorable safety profile, strong clinical proof-of-concept, and plans to advance the candidate into Phase 2b development for eosinophilic esophagitis.